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Mycobacterium vaccae (NCTC 11659) is an environmental saprophytic bacterium with anti-70 
inflammatory, immunoregulatory, and stress resilience properties. Previous studies have shown 71 
that whole, heat-killed preparations of M. vaccae prevent allergic airway inflammation in a 72 
murine model of allergic asthma. Recent studies also demonstrate that immunization with M. 73 
vaccae prevents stress-induced exaggeration of proinflammatory cytokine secretion from 74 
mesenteric lymph node cells stimulated ex vivo, prevents stress-induced exaggeration of 75 
chemically-induced colitis in a model of inflammatory bowel disease, and prevents stress-76 
induced anxiety-like defensive behavioral responses. Furthermore, immunization with M. vaccae 77 
induces anti-inflammatory responses in brain, and prevents stress-induced exaggeration of 78 
microglial priming. However, the molecular mechanisms underlying anti-inflammatory effects of 79 
M. vaccae are not known. We have purified and identified a unique anti-inflammatory 80 
triglyceride, 1,2,3-tri[Z-10-hexadecenoyl]glycerol, from M. vaccae and evaluated its effects in 81 
freshly isolated murine peritoneal macrophages. The free fatty acid form of 1,2,3-tri[Z-10-82 
hexadecenoyl]glycerol, 10(Z)-hexadecenoic acid, decreased lipopolysaccharide-stimulated 83 
secretion of the proinflammatory cytokine IL-6 ex vivo. Meanwhile, next generation mRNA 84 
sequencing revealed that pretreatment with 10(Z)-hexadecenoic acid upregulated genes 85 
associated with peroxisome proliferator-activated receptor alpha (PPARα) signaling in 86 
lipopolysaccharide-stimulated macrophages, in association with a broad transcriptional 87 
repression of inflammatory markers. We confirmed using luciferase-based transfection assays 88 
that 10(Z)-hexadecenoic acid activated PPARα signaling, but not PPARγ, PPARδ, or retinoic 89 
acid receptor (RAR) α signaling. The effects of 10(Z)-hexadecenoic acid on lipopolysaccharide-90 
stimulated secretion of IL-6 were prevented by PPARα antagonists and absent in PPARα-91 
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deficient mice. Future studies should evaluate the effects of 10(Z)-hexadecenoic acid on stress-92 
induced exaggeration of peripheral inflammatory signaling, central neuroinflammatory signaling, 93 
and anxiety- and fear-related defensive behavioral responses. 94 
KEYWORDS 95 
10(Z)-hexadecenoic acid, bacteria, inflammation, interleukin 6, lipid, macrophage, mycobacteria, 96 
PPAR, RNAseq, vaccae 97 
ABBREVIATIONS 98 
CD, cluster of differentiation 99 
CNS, central nervous system 100 
DC, dendritic cell 101 
DSM-5, Diagnostic and Statistical Manual of Mental Disorders (5th ed.). 102 
IL, interleukin 103 
IFN, interferon 104 
IRF, interferon regulatory factor 105 
LPS, lipopolysaccharide 106 
MGB, microbiota–gut–brain 107 
NCTC, National Collection of Type Cultures 108 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells 109 
PEA, palmitoylethanolamide 110 
PPAR, peroxisome proliferator-activated receptor 111 
PTSD, posttraumatic stress disorder 112 
RAR, retinoic acid receptor  113 
TGFβ, transforming growth factor beta 114 
TLR, toll-like receptor 115 




The global prevalence of anxiety disorders has been estimated to be 7.3%, ranging from 5.3% in 118 
African cultures to 10.4% in Euro/Anglo cultures (Baxter et al. 2013). According to the 119 
Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (DSM-5; (American Psychiatric 120 
Association 2013)), anxiety disorders include those that share features of excessive fear and 121 
anxiety and related behavioral disturbances, such as generalized anxiety disorder, panic disorder, 122 
social anxiety disorder (social phobia), and specific phobia (American Psychiatric Association 123 
2013). Posttraumatic stress disorder (PTSD), although formerly classified as an anxiety disorder, 124 
is classified as a trauma- and stressor-related disorder (APA, 2013). Collectively, anxiety and 125 
trauma-related disorders are complex and multifactorial, and their differentiation and 126 
management are complicated by phenotypic heterogeneity. The etiology and pathophysiology of 127 
these disorders are thought to involve interactions among the genome, epigenome, and 128 
environment (Nugent et al. 2011). Recently, investigation of the etiology and pathophysiology of 129 
psychiatric and neurological diseases has expanded to include a potential role of the microbiota–130 
gut–brain (MGB) axis (Forsythe et al. 2010; Cryan and Dinan 2012, 2015; Leclercq et al. 2016). 131 
Of particular interest, evidence from preclinical and clinical studies suggests that exaggerated 132 
inflammation, which in some cases may be secondary to dysregulation of the microbiome, may 133 
be a risk factor for the development of trauma- and stressor-related disorders (for review, see 134 
(Langgartner et al. 2018)). These studies raise the question of whether or not microbial-based 135 
interventions with anti-inflammatory or immunoregulatory properties may have value in the 136 
prevention or treatment of trauma- and stressor-related disorders. 137 
Evidence suggests that some common pathogenic and non-pathogenic microorganisms, to which 138 
humans have been exposed throughout evolution, drive anti-inflammatory and 139 
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immunoregulatory mechanisms that inhibit inappropriate immune responses by the host (Rook 140 
and Rosa Brunet 2002; Rook 2009, 2010; Okada et al. 2010). Throughout human evolution, the 141 
interactions between these ancestral microorganisms, which we have collectively referred to as 142 
“Old Friends”, and the innate immune system promoted immunoregulation. These “Old Friends” 143 
included microorganisms that: 1) were part of host physiology (human microbiota); 2) were 144 
harmless but inevitably contaminating air, food and water (environmental microbiota); or 3) led 145 
to severe host tissue damage when attacked by the host immune system (e.g., helminthic 146 
parasites) (Rook 2013; Blaser 2017).  147 
“Old Friends” are thought to suppress host inflammation through a variety of mechanisms, 148 
including the induction of specific subsets of antigen-presenting cells such as macrophages and 149 
dendritic cells (DCs) and modulation of innate immunity (Le Bert et al. 2011; Garn et al. 2016; 150 
Lowry et al. 2016). In their absence, the host may develop inappropriate immune responses to 151 
allergens, self-antigens, or gut microbiota. It has been hypothesized that increases in allergies, 152 
autoimmune diseases, inflammatory bowel diseases, and psychiatric disorders in modern living 153 
conditions may be due, in part, to decreased exposure to “Old Friends” (Rook 2010; Lyte and 154 
Cryan 2014; Bloomfield et al. 2016; Lowry et al. 2016; Stamper et al. 2016). In parallel, 155 
individuals with a diagnosis of PTSD have a higher risk of development of any autoimmune 156 
disease, relative to those with other psychiatric disorders, or relative to those with no psychiatric 157 
disorder (O’Donovan et al. 2015), suggesting that impaired immunoregulation or inappropriate 158 
inflammation may confer risk for development of both autoimmune conditions and PTSD. The 159 
saprophytic mycobacterium, Mycobacterium vaccae (National Collection of Type Cultures 160 
(NCTC) 11659), has shown encouraging therapeutic potential in diseases of inflammation and 161 
immunodysregulation (Gutzwiller et al. 2007; Rook et al. 2007), and has shown 162 
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immunoregulatory and stress-protective effects in murine models (Zuany-Amorim et al. 2002; 163 
Adams et al. 2004; Lowry et al. 2007; Reber et al. 2016; Fox et al. 2017; Frank et al. 2018). 164 
Mycobacteria are abundant in municipal water supplies (Gebert et al. 2018) and are a normal 165 
component of the healthy human microbiome of the oral cavity (buccal mucosa and dental 166 
plaque) and upper respiratory tract (nostrils and oropharynx), and therefore are considered part of 167 
the microbiome of the upper airways (Macovei et al. 2015). 168 
The identification of specific microbially-derived molecules with anti-inflammatory or 169 
immunoregulatory properties may provide novel therapeutic avenues for the treatment of 170 
diseases of immunodysregulation, or trauma- and stressor-related disorders where exaggerated 171 
inflammation is thought to be a risk factor (Lowry et al. 2016; Langgartner et al. 2018). We have 172 
previously shown that treatment with a heat-killed preparation of the saprophytic 173 





Tregs (Zuany-Amorim et al. 2002). These cells are allergen-specific and upon 175 
passive transfer can protect recipient allergic mice from airway inflammation by significantly 176 
reducing eosinophilia in the lungs. In addition, treatment with M. vaccae induces a population of 177 
pulmonary CD11c
+
 antigen-presenting cells, which are characterized by increased expression of 178 
IL-10, transforming growth factor beta (TGFβ) and interferon α (IFNα) (Adams et al. 2004). 179 
Furthermore, at least in vitro, priming of human DCs with M. vaccae induces strong inhibition of 180 
Th2 responses (Le Bert et al. 2011).  181 
Meanwhile, we’ve shown that immunization of mice with M. vaccae promotes a more proactive 182 
response to a chronic psychosocial stressor, prevents stress-induced colitis, prevents stress-183 
induced exaggeration of chemically-induced colitis in a model of inflammatory bowel disease, 184 
and attenuates anxiety-like defensive behavioral responses (Reber et al. 2016). Consistent with 185 
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these findings, immunization with M. vaccae prevents stress-induced exaggeration of interferon 186 
gamma and IL-6 secretion from freshly isolated mesenteric lymph node cells stimulated with 187 
anti-CD3/anti-CD28 ex vivo. Importantly, preimmunization with M. vaccae, in stressed mice, 188 
resulted in a two orders of magnitude increase in IL-10 secretion from mesenteric lymph node 189 
cells stimulated ex vivo. However, until now, specific constituents of M. vaccae that suppress 190 
inflammation in macrophages in the periphery or central nervous system have not been 191 
identified. 192 
Through a screening process of M. vaccae NCTC 11659 lipid extracts, a single triglyceride, 193 
1,2,3-tri[Z-10-hexadecenoyl]glycerol, was identified with potential immunotherapeutic benefits 194 
(Rosa Brunet and Rook 2008). The lipid was demonstrated to prevent allergic airway 195 
inflammation, and the lipid recapitulated the therapeutic effects of whole heat-killed M. vaccae. 196 
The protective phenotype was characterized by increased IL-10, decreased IL-5, and reduced 197 
infiltration of eosinophils and macrophages in bronchoalveolar lavage fluid (Rosa Brunet and 198 
Rook 2008). It was also shown that the efficacy of the triglyceride was not dependent on the 199 
glycerol structure, as the synthetic, constituent free fatty acid, 10(Z)-hexadecenoic acid, was 200 
sufficient to suppress pulmonary airway inflammation. The mechanism through which this long-201 
chain, monounsaturated fatty acid was capable of limiting symptoms of inflammation is 202 
unknown, but it is explored here in a model of macrophage activation.  203 
Notably, it is relatively rare in nature for an organism to naturally produce a fatty acid that is 204 
unsaturated at the C10 position, yet several mycobacteria species—including M. vaccae, can 205 
perform that desaturation (Scheuerbrandt and Bloch 1962; Coyle et al. 1992; Böttger et al. 1993; 206 
Springer et al. 1993; Suutari and Laakso 1993; Chou et al. 1998; Tay et al. 1998; Pacífico et al. 207 
2018). We successfully synthesized the free fatty acid, 10(Z)-hexadecenoic acid, and using cell-208 
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based assays and RNA-seq, revealed that 10(Z)-hexadecenoic acid upregulated genes associated 209 
with the peroxisome proliferator-activated receptor (PPAR) signaling pathway and inhibited 210 
proinflammatory signaling of activated macrophages ex vivo. Furthermore, studies using cultured 211 
cells transfected with lipid-regulated transcription factors revealed that both the 212 
monoacylglycerol lipid constituent of M. vaccae and its free fatty acid form selectively increased 213 
PPARα signaling. The effects of 10(Z)-hexadecenoic acid to inhibit proinflammatory signaling 214 
of activated macrophages ex vivo were prevented by PPARα antagonists and absent in PPARα-215 
deficient mice. This is the first report, to our knowledge, to show that a synthetic M. vaccae-216 
derived lipid acts to induce anti-inflammatory responses in host immune cells by acting as an 217 
agonist at host PPARα receptors. 218 
MATERIALS AND METHODS 219 
Animals 220 
Adult male BALB/c mice (BALB/cAnHsd; Cat. No. 047; Harlan, Indianapolis, IN, USA), 6-8 221 
weeks old, were used and housed under standard conditions with food and water available ad 222 




/J; Cat. No. 008154; Jackson Laboratories, 223 
Bar Harbor, ME, USA) and control mice (C57BL/6J; Cat. No. 000664; Jackson Laboratories), 6-224 
8 weeks old, were used and housed under standard conditions with food and water available ad 225 





/J; Jackson Laboratories) future studies should ideally 227 
compare PPARα
–/–
 mice to wild type littermates. 228 
All experimental protocols were consistent with the National Institutes of Health Guide for the 229 
Care and Use of Laboratory Animals, Eighth Edition (The National Academies Press, 2011) and 230 
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the Institutional Animal Care and Use Committee at the University of Colorado Boulder 231 
approved all procedures. This work was covered under CU Boulder IACUC Protocol Numbers 232 
2134-14MAY2018 and 2361-14MAY2018-DT.  The research described here was conducted in 233 
compliance with The ARRIVE Guidelines: Animal research: reporting of in vivo experiments, 234 
originally published in PLOS Biology, June 2010 (Kilkenny and Altman 2010). All possible 235 
efforts were made to minimize the number of animals used and their suffering. 236 
Synthesis of 10(Z)-hexadecenoic acid; (10Z)-hexadec-10-enoic acid (CAS No. 2511-97-9) 237 
Unless otherwise noted, reagents were obtained commercially and used without further 238 
purification. Dichloromethane (CH2Cl2) was distilled over calcium hydride (CaH2) under a 239 
nitrogen atmosphere. Tetrahydrofuran (THF; (CH2)4O) was distilled from sodium-benzophenone 240 
under a nitrogen atmosphere. Thin-layer chromatography analysis of reaction mixtures was 241 
performed on Dynamic Adsorbents, Inc., silica gel F-254 TLC plates. Flash chromatography was 242 
carried out on Zeoprep 60 ECO silica gel. 
1
H spectra were recorded with a Varian INOVA 500 243 
spectrometer. Compounds were detected by monitoring UV absorbance at 254 nm. 244 
To a 5 mL sealed tube containing 1-heptene (0.50 mL, 3.55 mmol), methyl 10-undecenoate 245 
(0.080 mL, 0.36 mmol) and 0.35 mL THF was added to a Grubbs Z-selective metathesis catalyst 246 
(2.2 mg, 3.48 µmol, Cat. No. 771082, Sigma-Aldrich, St. Louis, MO, USA). The reaction was 247 
stirred at 45 
o
C for 8 h before cooling to room temperature. The slurry was filtrated through a 248 
short plug of silica gel and concentrated. The obtained oil was dissolved in 1.0 mL THF. The 249 
solution was cooled to 0 
o
C, then 9-borabicyclo[3.3.1]nonane (9-BBN) solution in THF (1.28 250 
mL, 0.50 M, 0.64 mmol) was added. After 2 h stirring at 0 
o
C, the reaction was quenched with 60 251 
µL EtOH, then 1.5 mL pH 7 potassium phosphate buffer and 1.5 mL 30% H2O2. The mixture 252 
was stirred at room temperature for 12 h, then extracted with 5 mL EtOAc three times. The 253 
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combined organic layers were washed with 4 mL saturated Na2S2O3 and 3 mL brine, then dried 254 
over Na2SO4, filtered and concentrated. To the crude oil in 1.0 mL THF was added LiOH 255 
monohydrate (38 mg, 0.90 mmol) in 1.0 mL water. After 2 h, the reaction solution was cooled to 256 
0 
o
C before addition of 0.91 mL 1.0 N HCl. After being concentrated under reduced pressure, the 257 
aqueous solution was saturated with NaCl and extracted with 3 mL dichloromethane three times. 258 
The combined organic layers were dried over Na2SO4, filtered and concentrated. Purification by 259 
flash chromatography (2:1:1 hexanes/dichloromethane/diethyl ether) provided (10Z)-hexadec-260 
10-enoic acid (0.022 g, 90%) as a colorless oil. 
1
H NMR (500 MHz, CDCl3): δ 5.48 – 5.22 (m, 261 
2H), 2.35 (t, J = 7.5 Hz, 2H), 2.01 (q, J = 6.6 Hz, 4H), 1.63 (p, J = 7.4 Hz, 2H), 1.35 – 1.15 (m, 262 
16H), 0.88 (t, J = 6.9 Hz, 3H). 263 
Murine peritoneal macrophage isolation and screening 264 
Murine peritoneal macrophages were isolated and cultured as previously described (Zhang et al. 265 
2008) and used to determine the effects of 10(Z)-hexadecenoic acid on lipopolysaccharide-266 
induced IL-6 secretion. Briefly, mice received a single injection of 3% thioglycollate medium (1 267 
mL, i.p.; Cat. No. 9000-294, VWR, Radnor, PA, USA). Mice were euthanized 96 h later using 268 
cervical dislocation, and macrophages were collected in Dulbecco’s phosphate-buffered saline 269 
(DPBS; Cat. No. 14190136, Invitrogen, Carlsbad, CA, USA). Cells were centrifuged and 270 
resuspended in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12; Cat. 271 
No. 10565018, Invitrogen) supplemented to be 10% (v/v) fetal bovine serum (Cat. No. 272 
16000036, Invitrogen) and 1% penicillin/streptomycin (Cat. No. 15140148, Invitrogen). One 273 
mouse yielded enough cells for one experimental replicate. 1 x 10
5
 cells/well were allowed to 274 
adhere for 1.5 h before being washed with DPBS. 10(Z)-hexadecenoic acid was dissolved in 275 
DMEM/F-12 with 0.5% (v/v) dimethyl sulfoxide (Cat. No. D8418, Sigma-Aldrich). The 276 
14 
 
macrophages were incubated with either 10(Z)-hexadecenoic acid (0.4 µM, 4 µM, 20 µM, 100 277 
µM, 500 µM, 1000 µM) or DMEM/F-12 for 1 h before being stimulated with either 1 µg/ml 278 
lipopolysaccharide (serotype 0127:B8, Sigma-Aldrich, St. Louis, MO, USA) or DMEM/F-12. 279 
Culture supernatants were collected at 6, 12, and 24 h post-stimulation.  280 
Cytokine measurements  281 
Cell culture supernatants (10 µl) from freshly isolated peritoneal macrophages were diluted 282 
1:200, and IL-6 was measured using ELISA (Cat. No. 431304, BioLegend, San Diego, CA, 283 
USA). The assay has a minimal detectable concentration of 2 pg/ml IL-6. All samples were 284 
measured using duplicate wells in the ELISA. 285 
Cytotoxicity assay 286 
Cytotoxicity was determined using the sulforhodamine B (SRB) colorimetric assay, as 287 
previously described (Vichai and Kirtikara 2006). Briefly, without removing the culture media, 288 
cells were fixed by adding cold trichloroacetic acid and incubated at 4 °C for 1 h. The plates 289 
were washed with slow-running tap water and set out to dry overnight. Then, 0.057% SRB (Cat. 290 
No. AC333130050, Fisher, Pittsburgh, PA, USA), solubilized in 10 mM Tris (Cat. No. BP153, 291 
Fisher), was added to each well. After 30 min, plates were washed with 1% acetic acid and set 292 
out to dry overnight. SRB was measured at 490 nm on a Synergy HT microplate reader (Part 293 
Number 7091000, Biotek, Winooski, VT, USA). Cell viability was expressed as the ratio of 294 
experimental and control growth.   295 
Ligands 296 
For studies using reporter gene assays following transfection of COS1 cells, rosiglitazone, 297 
troglitazone, and WY14643 were obtained from Alexis Biochemicals (San Diego, CA, USA); 298 
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ATRA and AM580 were obtained from Sigma-Aldrich. In addition, GW9662 was a gift from 299 
T.M. Willson (GlaxoSmithKline, Brentford, United Kingdom). For experiments using freshly 300 
isolated peritoneal macrophages, GW 6471 (Cat. No. 4618), GW 9662 (Cat. No. 1508), GSK 301 
0660 (Cat. No. 3433), WY 14643 (Cat. No. 1312), rosiglitazone (Cat. No. 5325), GW 0742 (Cat. 302 
No. 2229) were obtained from Tocris Bioscience (Bristol, United Kingdom).  303 
Transfections and reporter gene assays 304 
Cells were transfected with the following receptor and reporter constructs: Gal4-PPARα-LBD, 305 
Gal4-PPARγ-LBD, Gal4-PPARδ-LBD, Gal4-RARα-LBD, pMH100-TK-luc, and pCMX-β-306 
galactosidase (Chen and Evans 1995). All transfection experiments were performed with COS1 307 
cells using polyethylenimine (Sigma-Aldrich) reagent (Szatmari et al. 2006). After 6–8 h of the 308 
transfection, the medium was replaced with DMEM medium containing the indicated ligands or 309 
vehicle (as control) (Chen and Evans 1995; Benko et al. 2003). Cells were lysed and assayed for 310 
reporter expression 18 h after transfection. The luciferase assay system (Promega, Madison, WI, 311 
USA) was used as described previously (Nagy et al. 1999). Measurements were carried out with 312 
a Wallac Victor-2, multilabel counter. Luciferase activity of each sample was normalized to the 313 
β-galactosidase activity. 314 
RNA extraction and library preparation 315 
Total RNA content of 1 x 10
5
 macrophages pretreated for 1 h with 200 μM 10(Z)-hexadecenoic 316 
acid (utilizing separate macrophage preparations from n = 3 mice) or vehicle (utilizing separate 317 
macrophage preparations from n = 3 mice) and stimulated with 1 µg/ml LPS was extracted using 318 
TRI Reagent® (Cat. No. T9424, Sigma-Aldrich) according to manufacturer’s instructions. The 319 
RNA input was quantified on a Qubit
TM
 3.0 Fluorometer (Cat. No. Q33216, Thermo Fisher, 320 
Waltham, MA, USA) to ensure there was sufficient starting material. The RNA sequencing 321 
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libraries were generated with the NEBNext rRNA Depletion Kit (Cat. No. E6310, New England 322 
BioLabs) in order to enrich the samples in mRNA, and NEBNext Ultra Directional RNA Library 323 
Prep Kit for Illumina (Cat. No. 7240, New England BioLabs). Briefly, mRNA was purified from 324 
100 ng of total RNA, fragmented, and converted to double stranded cDNA. Barcodes were 325 
ligated to the cDNA fragments, and prior to PCR enrichment of the library, the cDNA product 326 
was quantified on a Qubit 3.0 Fluorometer (Thermo Fisher). The integrity of the purified oligo 327 
libraries was evaluated on an Agilent Bioanalyzer 2100 (Cat. No. G2939BA, Agilent, Santa 328 
Clara, CA, USA). 329 
Sequencing 330 
Libraries were sequenced at the Next Generation Sequencing Facility at the University of 331 
Colorado Boulder. The libraries were multiplexed and sequenced on an Illumina HiSeq 2000 332 
Sequencing System (Cat. No. SY-401-1001, Illumina, San Diego, CA, USA). For each sample, 333 
paired-end 100-bp reads were sequenced using V3 chemistry. 334 
RNA read processing, mapping, and differential expression 335 
Quality analysis of sequencing data was done using FastQC. The adaptors and low quality raw 336 
reads were cut with Trimmomatic (version 0.32) (Bolger et al. 2014). The reads were aligned to 337 
the mouse genome, mm10 (University of California, Santa Cruz, CA, USA), using the TopHat2 338 
sequence aligner (version 2.0.6) (Kim et al. 2013). Reads mapping to exon features were counted 339 
using HTseq (version 0.6.1) (Anders et al. 2015). The raw reads and count data have been 340 
deposited in the GEO database under accession number GSE125930. Differentially expressed 341 
genes were identified using the R package, DESeq (version 1.28.0) (Anders and Huber 2010).  342 
Statistical analysis 343 
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Data are presented as means ± SEM or means + SEM. Data were subjected to a normality test 344 
and one-way analysis of variance (ANOVA); Fisher’s least significant difference (LSD) tests 345 
were performed as appropriate. A two-tailed p value  0.05 was considered significant. ELISA 346 
IL-6 data were analyzed using linear mixed effects models using the software package SPSS 347 
(version 21.0, SPSS Inc., Chicago, IL, USA). Network visualizations were created in Cytoscape 348 
(version 3.5.1) using an enrichment map plug-in (Merico et al. 2011). 349 
RESULTS 350 
10(Z)-hexadecenoic acid decreases LPS-induced secretion of IL-6 in macrophages 351 
To simulate inflammation, freshly isolated mouse peritoneal macrophages were challenged with 352 
LPS (1 µg/mL) ex vivo (outlined in Fig. 1). Macrophages that were cultured in the presence of 353 
10(Z)-hexadecenoic acid (0.4 µM, 4 µM, 20 µM, 100 µM, 500 µM, 1000 µM) for 1 h prior to 1 354 
µg/mL LPS stimulation secreted less IL-6 relative to macrophages cultured with media alone 355 
prior to LPS stimulation (Fig. 2A-C) (F(1,111) = 15.20, p < 0.001). This difference was observable 356 
as early as 6 h after LPS challenge, and was sustained for at least 24 h. We selected the 6 h, 12 h, 357 
and 24 h time points for measurement of IL-6 as previous studies have shown increased IL-6 358 
secretion using LPS-stimulated peritoneal macrophage cultures in mice at these time points, with 359 
linear increases in IL-6 up to the 24 h time point (Shacter et al. 1993; Wollenberg et al. 1993; Lin 360 
and Tang 2007; Lee et al. 2015; Arteaga Figueroa et al. 2017). The effect also appeared to be 361 
concentration and time dependent. The lowest concentration of 10(Z)-hexadecenoic acid (0.4 362 
µM) was ineffective at 6 h, but reduced IL-6 secretion to 40% of control levels at 24 h. Using a 363 
constrained logistic model on the relative secretion of IL-6, we estimated the EC50 to be 823 364 
μM, 115 μM, and 190 μM at the 6h, 12h, and, 24h observations, respectively (Fig. 2). Post hoc 365 
pairwise comparisons of raw IL-6 values relative to paired media control values at the same time 366 
18 
 
point (n = 3 per group) are presented in Table S1. This time and concentration dependence may 367 
indicate that a receptor-mediated transcriptional change is occurring. In contrast to the effects of 368 
10(Z)-hexadecenoic acid on LPS-induced IL-6 secretion, it had no detectable effect on IL-6 369 
secretion by itself (IL-6 was undetectable in all conditions; Fig. S1). We cannot exclude the 370 
possibility, however, that 10(Z)-hexadecenoic acid by itself had effects on IL-6 secretion that 371 
were below the limit of detectability of the assay used (i.e., 2 pg/mL). Cell viability was 372 
measured to dispel the possibility that senescence or cell death was contributing to reduced IL-6 373 
secretion. Using a high concentration (1 mM) of 10(Z)-hexadecenoic acid, less than 40% of 374 
macrophages were viable at most time points. However, macrophages cultured with all other 375 
concentrations of 10(Z)-hexadecenoic acid studied (0.4 µM, 4 µM, 20 µM, 100 µM, 500 µM) 376 
were as viable as media controls (Fig. S2). 377 
Treatment with 10(Z)-hexadecenoic acid induces a broad anti-inflammatory 378 
transcriptional profile in LPS-stimulated macrophages 379 
To explore the potential effects of 10(Z)-hexadecenoic acid on transcriptional responses in LPS-380 
stimulated macrophages, we used RNA-seq. Murine peritoneal macrophages were incubated 381 
with 200 µM 10(Z)-hexadecenoic acid for 1 h prior to stimulation with LPS. Using IL-6 as a 382 
measure for the suppressive activity of 10(Z)-hexadecenoic acid, we estimated the EC50 at 12h to 383 
be 115 μM. The 200 μM concentration was chosen as it was sufficiently larger than the EC50, but 384 
less than a concentration that would affect macrophage viability. After 12 h, the RNA was 385 
extracted and depleted of rRNA. We selected the 12 h time point for measurement of mRNA 386 
using RNAseq as previous studies have shown increased IL-6 secretion using LPS-stimulated 387 
peritoneal macrophage cultures in mice at this time point, as well as the ability to suppress IL-6 388 
mRNA expression at this time point by interfering with a TLR4-MyD88-BLT2-Nox1-ROS-NF-389 
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κB pathway leading to IL-6 secretion (Lee et al. 2015). The cDNA libraries were sequenced in a 390 
100bp paired-end experiment generating 51-63 million reads per sample (Table S2; Fig. S3).  391 
For differential expression, we examined LPS-stimulated macrophages pretreated with either 392 
10(Z)-hexadecenoic acid or vehicle (GSE125930). Differentially expressed transcripts were 393 
identified using the R package, DESeq (Anders and Huber 2010). A total of 203 genes were 394 
found to be differentially expressed with an FDR-adjusted p < 0.1 (Table S3). Of the 203 395 
differentially expressed genes, 109 were downregulated in the 10(Z)-hexadecenoic acid 396 
condition, and 20% of those genes were associated with proinflammatory processes (Table S4). 397 
The top 20 differentially expressed genes are reported in Fig. 3A. Consistent with the ex vivo 398 
macrophage experiments measuring IL-6 protein with ELISA, the second most significantly 399 
differentially expressed transcript was IL-6 (Table S3). 400 
PPARα regulated genes are associated with 10(Z)-hexadecenoic acid treatment in LPS-401 
stimulated macrophages 402 
To better understand the pathways affected by 10(Z)-hexadecenoic acid treatment, the list of 203 403 
differentially expressed genes were queried against the Database for Annotation, Visualization 404 
and Integrated Discovery (DAVID) (Huang et al. 2009). Within the top 40 most significantly 405 
enriched KEGG pathways, 34 (i.e., 85%) were related to disease or inflammation (Table S5). In 406 
addition, 32 of the top 40 most significantly enriched KEGG pathways (i.e., 82%) were 407 
exclusively enriched for genes that were significantly downregulated by treatment with 10(Z)-408 
hexadecenoic acid. Among these most significantly affected pathways, there was a wide scope of 409 
immunological context, which included infections, diseases, cytokine signaling, and various 410 
inflammatory pathways. The top 5 pathways with genes that were exclusively downregulated by 411 
treatment with 10(Z)-hexadecenoic acid are reported in Fig. 3C. 412 
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While the majority of pathways with genes affected by 10(Z)-hexadecenoic acid involved genes 413 
that were exclusively downregulated by 10(Z)-hexadecenoic acid, some pathways involved 414 
genes that were exclusively upregulated by 10(Z)-hexadecenoic acid. Of the top 40 pathways, 7 415 
(i.e., 17.5%) pathways were exclusively enriched for genes that were significantly upregulated 416 
by treatment with 10(Z)-hexadecenoic acid. Overall, of 203 genes that were differentially 417 
expressed following treatment with 10(Z)-hexadecenoic acid, 93 genes (46%) were upregulated. 418 
The pathways with detectable enrichment involved regulation of lipolysis in adipocytes, 419 
glycerolipid metabolism, circadian entrainment, PPAR signaling pathway, and extracellular 420 
matrix-receptor interaction (Fig. 3B). The top 5 pathways with genes that were exclusively 421 
upregulated by treatment with 10(Z)-hexadecenoic acid are reported in Fig. 3B. The PPAR 422 
signaling pathway was among the top 5 most-enriched KEGG pathways with genes that were 423 
exclusively upregulated by treatment with 10(Z)-hexadecenoic acid (Fig. 3B).  424 
In a secondary analysis, rather than rely on a subset of genes for biological interpretation, we 425 
used all expression data in Gene Set Enrichment Analysis (GSEA). We queried all detected 426 
transcripts against the KEGG pathways database (c2.cp.kegg.v6.2), and the top 5 enriched gene 427 
sets for the 10(Z)-hexadecenoic acid phenotype were: “peroxisome” (KEGG: hsa04146), a main 428 
site of fatty acid oxidation via the β-oxidation cycle, “ppar_signaling_pathway” (KEGG: 429 
hsa03320), “citrate_cycle_tca_cycle” (KEGG: hsa00020), “fatty_acid_metabolism” (KEGG: 430 
hsa00071), and “propanoate_metabolism” (KEGG: hsa00640) (Table S6). Of potential interest, 431 
four of these KEGG pathways, “peroxisome” (KEGG: hsa04146), “ppar_signaling_pathway” 432 
(KEGG: hsa03320), “fatty_acid_metabolism” (KEGG: hsa00071), and 433 
“propanoate_metabolism” (KEGG: hsa00640) were also found to be enriched in livers from 24 h 434 
fasted PPARα+/+ relative to PPAR-/- mice, while “peroxisome” (KEGG: hsa04146), 435 
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“ppar_signaling_pathway” (KEGG: hsa03320), and “fatty_acid_metabolism” (KEGG: 436 
hsa00071), were found to be enriched in livers from wild type mice treated with the PPARα 437 
agonist Wy14643, relative to vehicle (Kersten 2014). Together, these studies support a 438 
convergence of 10(Z)-hexadecenoic acid effects on PPARα signaling pathways induced by 439 
physiological or pharmacological stimuli. Propionate is one of the short-chain fatty acids, which 440 
are emerging as key mediators and regulators of host-microbe cross-talk, with a significant 441 
impact on host metabolism, including as an energy source (Hoyles et al. 2018). All 5 gene sets 442 
were significant with an unadjusted p value < 0.05, but failed to reach significance using FDR-443 
adjusted p values; nevertheless, the overall pattern is consistent with a modulation of lipid 444 
metabolism. In a network visualization of gene set overlap between all detected pathways using 445 
DAVID, PPARs and peroxisomal lipid metabolism were prominent vertices (Fig. 3D). We also 446 
searched against the collection of transcription factor binding motifs (c3.tft.v6.0), which revealed 447 
enrichment for CREB, Gfi1, and PPARα cis-regulatory motifs upstream of the genes upregulated 448 
with 10(Z)-hexadecenoic acid treatment in LPS-stimulated macrophages (Table S7). Again, these 449 
were nominally significant (i.e. p < 0.05; q > 0.05), but these findings bolster PPARs, and 450 
specifically PPARα, as a potential receptor mediating anti-inflammatory effects of 10(Z)-451 
hexadecenoic acid. 452 
Downstream signaling of TLR4 is inhibited with 10(Z)-hexadecenoic acid treatment 453 
NF-κB is one of three major transcription factors downstream of LPS-induced activation of toll-454 
like receptor 4 (TLR4), the other two being IRF3 and AP-1 (Kawasaki and Kawai 2014). Using 455 
all expression data in GSEA, we found that pretreatment with 10(Z)-hexadecenoic acid, relative 456 
to treatment with vehicle, prior to LPS stimulation, downregulated signaling pathways 457 
downstream from TLR4, such as NF-κB and IRF3, but not AP-1. In a network visualization of 458 
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the most significant pathways (FDR < 0.1), there is a bifurcation at the 459 
“ZHOU_INFLAMMATORY_RESPONSE_LPS” node representing the NF-κB and IRF3 460 
responses (Fig. 4A). Among all nodes in this network, we counted and ranked the occurrence of 461 
enriched transcripts. The counts for the highest ranking transcripts were categorized into either 462 
NF-κB regulated responses or IRF regulated responses (Fig. 4B). We also examined enrichment 463 
for transcription factor motifs and detected enrichment for NF-κB, IRF1, IRF2, and IRF_Q6 464 
among others, in transcripts associated with the vehicle treated, LPS stimulated group (Table 465 
S8). Alternatively, this can be understood to mean that mRNA transcripts that are located near 466 
those transcription factor binding sites are downregulated in 10(Z)-hexadecenoic acid treated, 467 
LPS-stimulated macrophages. To better understand the classification of the IRF_Q6 gene set (N 468 
= 242 genes) and differentially expressed genes (q < 0.1, N = 203 genes), they were both queried 469 
against the Interferome database (Rusinova et al. 2013). There are three types of interferons 470 
(IFNs), namely type I (composed of α, β, κ, ε, and ω subtypes), type II (IFNγ) and type III 471 
(IFNλ; also called IL28 and IL29), which are distinguished by having distinct genetic loci, amino 472 
acid sequence homology and specific cognate receptors (Pestka et al. 2004). This analysis 473 
revealed that a vast majority of the differentially expressed genes are regulated by both type I 474 
and II interferon responses (Fig. 4C), consistent with the hypothesis that 10(Z)-hexadecenoic 475 
acid alters TLR4, IRF3, and interferon signaling. Of note, cells infected with Mycobacterium 476 
tuberculosis induce type I interferons, including IFNα and IFNβ, which are thought to promote 477 
infection with M. tuberculosis (Travar et al. 2016). Using enrichment tools, like GSEA and 478 
DAVID, these RNA-seq data suggest that both NF-κB and IRF3 pathways are downregulated in 479 
LPS-stimulated macrophages when treated with 10(Z)-hexadecenoic acid.  480 
The anti-inflammatory effects of 10(Z)-hexadecenoic acid are mediated through PPARα 481 
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10(Z)-hexadecenoic acid specifically activates PPARα 482 
Fatty acids can modulate inflammation via the activation of nuclear hormone receptors (Chinetti 483 
et al. 2000; Kidani and Bensinger 2012). Therefore, we assessed the nuclear receptor activation 484 
capacity of: 1) the triacylglycerol (TAG), 1,2,3-tri[Z-10-hexadecenoyl]glycerol; 2) the 485 
monoacylglycerol (MAG), 1-[Z-10-hexadecenoyl]glycerol; and 3) the free fatty acid (FFA), 486 
10(Z)-hexadecenoic acid. We conducted reporter gene assays via the transfection of COS1 cells 487 
using GAL4-fusion ligand binding domains (LBDs) of various lipid-activated nuclear receptors 488 
(PPARα-LBD, PPARγ-LBD, PPARδ-LBD and RARα-LBD) along with a plasmid carrying 489 
MH100-TK-luciferase reporter (Chen and Evans 1995). Transfected cells were incubated with 490 
TAG, MAG, or FFA for 18 h and relative luciferase activity, normalized to β-galactosidase 491 
activity, was measured. Each reporter transfection was validated with the respective receptor 492 
agonist (PPARα, WY-14643; PPARγ, rosiglitazone (RSG); PPARδ, GW1516; RARα, AM580). 493 
Both the MAG and FFA, at concentrations of 80 μM, reliably increased PPARα-, but not 494 
PPARγ-, PPARδ, or RARα-regulated reporter expression (Fig. 5A-D). The triglyceride had no 495 
effect (Fig. 5A-D). Together, these results demonstrate that 10(Z)-hexadecenoic acid and its 496 
monoacylglycerol form selectively activate the PPARα receptor.  497 
PPARα is required for anti-inflammatory effects of 10(Z)-hexadecenoic acid 498 
Next, we investigated if this interaction was necessary for inhibiting LPS-stimulated release of 499 
IL-6. Agonists and antagonists of each PPAR were used to test if PPARα has a singular role in 500 
this process. The agonists and antagonists and their receptor specificities are listed in Table S9 501 
Macrophages were incubated with a single PPAR antagonist for 1 h prior to treatment with either 502 
200 μM 10(Z)-hexadecenoic acid or a PPAR agonist complementary to its respective PPAR 503 
antagonist. After another 1 h incubation period, the cells were stimulated with LPS (1 µg/ml), 504 
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and IL-6 was measured 12 h later. Only with the PPARα antagonist, GW 6471, could the anti-505 
inflammatory effects of 10(Z)-hexadecenoic acid be significantly reversed (Fig. 6A). The effects 506 
of the PPARγ and –δ antagonists were comparable to media (Fig. 6A). These results suggest a 507 
selective interaction between 10(Z)-hexadecenoic acid and PPARα, as the PPARα antagonist, 508 
GW 6471, had no effect on macrophage viability (Fig. S4), while it was effective in reversing the 509 
anti-inflammatory effects of the PPARα agonist, WY-14643, as measured by IL-6 secretion in 510 
LPS-stimulated macrophages (Fig. S5). To further explore the role of PPARα in the anti-511 
inflammatory effects of 10(Z)-hexadecenoic acid, we repeated the assay with freshly isolated 512 
peritoneal macrophages from adult male C57BL/6J wild type and PPARα
-/-
 mice. As expected, 513 
10(Z)-hexadecenoic acid suppressed LPS-stimulated IL-6 in macrophages from wild type 514 
C57BL/6J mice, but this effect was absent in macrophages from PPARα KO mice (Fig. 6B). 515 
This indicated a full reversal of the anti-inflammatory effect of 10(Z)-hexadecenoic acid and the 516 
necessity of PPARα in mediating the effect. 517 
DISCUSSION 518 
Here we characterized the monounsaturated C16 free fatty acid, 10(Z)-hexadecenoic acid, 519 
derived from M. vaccae NCTC 11659, a saprophytic bacterium with anti-inflammatory and 520 
immunoregulatory properties that previously has been shown to prevent stress-induced 521 
exaggeration of peripheral inflammation and neuroinflammation, and to prevent stress-induced 522 
exaggeration of anxiety- and fear-related defensive behavioral responses. In addition, we showed 523 
that 10(Z)-hexadecenoic acid induced a broad transcriptional repression of inflammatory gene 524 
markers (see, for example, Table S10-11) and suppressed IL-6 secretion from freshly isolated, 525 
LPS-stimulated, murine peritoneal macrophages. Furthermore, we showed that both the 526 
monoacylated glycerol, 1-[Z-10-hexadecenoyl]glycerol and 10(Z)-hexadecenoic acid activated 527 
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PPARα signaling, as measured by transfection assays. Finally, we showed that PPARα 528 
antagonists prevented the anti-inflammatory effects of 10(Z)-hexadecenoic acid in macrophages, 529 
while the ex vivo effects of the lipid were absent in macrophages isolated from PPARα-deficient 530 
mice. 531 
Here we focused on effects of 10(Z)-hexadecenoic acid on peritoneal macrophages. Based on a 532 
number of lines of evidence, effects of 10(Z)-hexadecenoic acid actions on peritoneal 533 
macrophages may have important implications for CNS immunity and subsequent behavioral 534 
outcomes. Intraperitoneal administration of lipopolysaccharide is known to induce priming of 535 
hippocampal microglia and worsen CNS outcomes (Cunningham 2005, 2013; Cunningham et al. 536 
2009). Although the mechanisms through which peripheral inflammation signals to the CNS to 537 
induce microglial priming and neuroinflammatory responses are not entirely clear, a number of 538 
potential signaling mechanisms have been proposed. These include: 1) entry of cytokines into the 539 
brain at circumventricular organs that have a reduced blood-brain barrier; 2) binding of cytokines 540 
to cerebral vascular endothelium, inducing the secretion of central neuroinflammatory mediators; 541 
3) carrier-mediated transport of immune signals into the brain, across the blood-brain barrier; 4) 542 
migration of proinflammatory monocytes from the periphery to the CNS; and 5) activation of 543 
peripheral afferent nerves, including vagal and non-vagal pathways (Watkins et al. 1995; Maier 544 
et al. 1998; Maier 2003; Miller et al. 2010; Miller and Raison 2016). 545 
Together, these data support the hypothesis that bacterially-derived 10(Z)-hexadecenoic acid 546 
may induce a form of macrophage “inflammation anergy” (i.e., a condition characterized by an 547 
absence of the normal immune response to a particular antigen, see, for example, (Smythies et al. 548 
2005, 2010) through actions on PPARα. Peroxisome proliferator-activated receptors, PPARα, 549 
PPARγ, and PPARδ are ligand-activated nuclear receptors, each of which acts as a heterodimer 550 
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with retinoid X receptor (RXR), with potent anti-inflammatory properties, through interference 551 
with proinflammatory transcription factor pathways (Chinetti et al. 2003). PPARα
-/- 
mice have 552 
increased vulnerability to chemically-induced colitis, experimental autoimmune encephalitis 553 
(EAE, a model of multiple sclerosis) and experimentally-induced allergic asthma, consistent with 554 
the hypothesis that endogenous PPARα suppresses inflammatory signaling in these models (for 555 
review, (Bensinger and Tontonoz 2008)). Activation of PPARα in macrophages inhibits the 556 
production of proinflammatory response markers, including IL-6, IL-1β, TNF, and inducible 557 
nitric oxide synthase (Xu et al. 2005; Paukkeri et al. 2007). Interaction between PPARα and 558 
TLR4 signaling has been observed in other endogenous systems, like vascular smooth muscle 559 
cells, where responses to activation of TLR4 with LPS are mitigated by a PPARα agonist (Ji et 560 
al. 2010). The anti-inflammatory effects were mediated, in part, by a reduction of tissue inhibitor 561 
of metalloprotease-1 (TIMP-1), which was also reduced in our study (Table S3). PPARα-562 
mediated inhibition of TLR4 signaling has also been shown in enteric glial cells (Esposito et al. 563 
2014), and a potential downstream target of PPARα-mediated suppression, TRIF, is required for 564 
LPS-induced activation of microglia (Burfeind et al. 2018). TRIF KO mice have attenuated 565 
expression of Il6, Ccl2, and Cxcl2, which were all also suppressed in our study (Table S3), in the 566 
hypothalamus after peripheral LPS stimulation (Burfeind et al. 2018). Furthermore, bacterially-567 
derived agonists of PPARs have potential for modulation of host-acquired immunity; PPARs 568 
have been found to regulate T cell survival, activation, and CD4
+
 T helper cell differentiation 569 
into the Th1, Th2, Th17, and Treg lineages (Choi and Bothwell 2012).  570 
Synthesis of 10(Z)-hexadecenoic acid by mycobacteria may be an example of molecular mimicry 571 
of eukaryotic signaling. Endogenous host-derived agonists of PPARα include 16:1 isoforms of 572 
palmitoleic acid (Kliewer et al. 1997; Kota et al. 2005), a lipokine released from adipose cells. 573 
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Palmitoleic acid localizes predominantly to nuclear fractions, consistent with a nuclear 574 
mechanism of action in host cells (Foryst-Ludwig et al. 2015), and is potently anti-inflammatory 575 
(Chan et al. 2015). In addition, the endocannabinoid, palmitoylethanolamide (PEA), acts as an 576 
agonist at PPARα (Verme et al. 2005; Guida et al. 2017). Of interest to trauma- and stressor-577 
related psychiatric disorders, PEA induces potent antidepressant-like behavioral responses (Yu et 578 
al. 2011) and, through induction of cannabinoid 2 receptors, alters the phenotype of macrophages 579 
and microglia (Guida et al. 2017). Recent studies have demonstrated PEA increases biosynthesis 580 
of allopregnanolone, an endocannabinoid, in the spinal cord, brainstem, hippocampus and 581 
amygdala, effects that are associated with faster fear extinction learning and improvement of 582 
aggression in socially-isolated mice (Sasso et al. 2012; Locci and Pinna 2017; Pinna 2018). 583 
Future studies should determine if 10(Z)-hexadecenoic acid is sufficient to induce the enhanced 584 
fear extinction learning previously demonstrated using whole, heat-killed M. vaccae (Fox et al. 585 
2017), and to what extent these effects are mediated by PPARα. 586 
Mycobacteria are unique in that they accumulate triacylglycerols as intracellular lipophilic 587 
inclusions. For example, M. smegmatis accumulates triacylglycerols and the acyl chain 588 
composition varies depending on the growth medium (Garton et al. 2002). Monounsaturated 589 
fatty acids, C16:1 hexadecenoic acid and C18:1 octadecenoic acid were found to be high when 590 
bacteria were grown in nutrient rich Middlebrook 7H9 broth, relative to low-nitrogen Youmans’ 591 
broth, but highest when bacteria were grown in Youmans’ broth with monounsaturated oleic acid 592 
((9Z)-octadec-9-enoic acid) supplementation. Thus, it is possible that mycobacteria synthesize 593 
and store triacylglycerols using environmental fatty acids as substrates, potentially for export to 594 
the cell envelope and release. If so, it may be possible to modify the immunoregulatory and anti-595 
inflammatory potential of mycobacteria through modification of growth conditions. 596 
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Of potential importance, conjugated linoleic acids are bacterial metabolites. For example, 597 
specific members of the genus Lactobacillus, including Lactobacillus reuteri, and L. plantarum, 598 
as well as bifidobacteria, mediate the conversion of dietary linoleic acid into immunomodulatory 599 
conjugated linoleic acids (Coakley et al. 2003; Lee et al. 2003; Ogawa et al. 2005; Kishino et al. 600 
2013). Most of the conjugated linoleic acid produced is located in the extracellular space (~98%) 601 
(Lee et al. 2003; Roman-Nunez et al. 2007), suggesting that bacterially-derived conjugated 602 
linoleic acids may be metabolic signaling molecules that modulate the host immune response. 603 
These bacterially-derived fatty acid metabolites include 10-hydroxy-cis-12-octadecenoic acid 604 
(HYA), cis-9,trans-11-linoleic acid, trans-9,cis-11-linoleic acid, and cis-10,trans-12-linoleic 605 
acid (Lee et al. 2003; Miyamoto et al. 2015), among many others (Ogawa et al. 2005). Several of 606 
these bacterially-derived fatty acid metabolites are potent PPARα agonists (IC50 values from 140 607 
nM to 400 nM) (Moya-Camarena et al. 1999). Perhaps the closest analogue of 10(Z)-608 
hexadecenoic acid identified here is trans-10-octadecenoic acid, produced by L. plantarum from 609 
linoleic acid (Kishino et al. 2013) or γ-linolenic acid (Ogawa et al. 2005). Although, to the best 610 
of our knowledge, the efficacy of trans-10-octadecenoic acid at PPARα receptors is not known, 611 
production of 10(Z)-hexadecenoic acid and diverse conjugated linoleic acids, which then act at 612 
host PPARα receptors, may be a general strategy of commensal organisms to suppress host 613 
immune responses, and promote symbiotic relationships with the host. Consistent with this 614 
hypothesis, macrophages lining the gut mucosa are anergic, characterized by an inability to 615 
mount proinflammatory responses, despite avid phagocytic activity (Smythies et al. 2005), while 616 
lung airway macrophages are immunoregulatory (Strickland et al. 1996; Soroosh et al. 2013; 617 
Duan and Croft 2014). Recent studies have also identified α-linolenic acid-derived bacterial 618 
metabolites, 13-hydroxy-9(Z),15(Z)-octadecadienoic acid (13-OH) and13-oxo-9(Z),15(Z)-619 
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octadecadienoic acid (13-oxo), that induce differentiation of anti-inflammatory M2 macrophages 620 
through activation of G protein-coupled receptor 40 (GPR40) (Ohue-Kitano et al. 2018). 621 
Together, these data support the hypothesis that bacterially-derived “postbiotic” compounds, 622 
including fatty acid metabolites, have important beneficial effects on the host via diverse host 623 
receptor signaling mechanisms. 624 
Although we did not assess the effects of 10(Z)-hexadecenoic acid on DCs or immunoregulation, 625 
defined as the balance between regulatory and effector T cells, conjugated linoleic acid 626 
suppresses NF-κB signaling and IL-12 production in DCs through IL-10 production (Loscher et 627 
al. 2005). Exposure of murine DCs to conjugated linoleic acid suppresses their ability to promote 628 
differentiation of naïve T cells into Th1 and/or Th17 cells in vitro following their adoptive 629 
transfer in vivo (Draper et al. 2014). Future studies should investigate the effects of 10(Z)-630 
hexadecenoic acid on inflammatory signaling in macrophages, DCs, as well as on T cell 631 
differentiation and function, the potential role of PPARα in these effects, and consequences for 632 
stress-induced exaggeration of anxiety- and fear-related behavioral responses. 633 
Overall, our data suggest that chemical mimicry of eukaryotic signaling molecules may be 634 
common among environmental bacteria, including mycobacteria (Gebert et al. 2018), that are 635 
abundant in host mucosal surfaces (Macovei et al. 2015), and bacterially-derived anti-636 
inflammatory lipids have potential as a novel approach to therapeutic intervention in 637 
inflammatory disease and stress-related psychiatric disorders, where immunodysregulation and 638 
inappropriate inflammation have been identified as risk factors (Rohleder 2014; Langgartner et 639 
al. 2018). 640 
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FIGURE LEGENDS 652 
Fig. 1 Experimental timeline for ex vivo macrophage stimulation. 653 
Abbreviations: FFA; free fatty acid, LPS, lipopolysaccharide. 654 
Fig. 2 Anti-inflammatory effects of 10(Z)-hexadecenoic acid in freshly-isolated murine 655 
peritoneal macrophages. 656 
Freshly isolated murine peritoneal macrophages were incubated for 1 h with synthetic 10(Z)-657 
hexadecenoic acid (0.4 µM, 4 µM, 20 µM, 100 µM, 500 µM, 1000 µM), then challenged with 658 
lipopolysaccharide (LPS; 1 µg/mL). Cell supernatants were collected at (A) 6 h, (B) 12 h, and 659 
(C) 24 h after lipopolysaccharide (LPS) challenge. Interleukin (IL) 6 concentrations in the 660 
supernatant were determined using enzyme-linked immunosorbent assay (ELISA) and reported 661 
relative to media-only controls (n = 6 replicates, with each replicate using different freshly 662 
isolated peritoneal macrophages; each sample was run using duplicate wells in the ELISA). Data 663 
were fit with a logistic function, which was used to estimate the EC50. Data are expressed as 664 
mean  SEM. 665 
Fig. 3 Gene networks upregulated following pretreatment with 10(Z)-hexadecenoic acid in 666 
LPS-stimulated macrophages suggest anti-inflammatory effects are mediated by PPARα. 667 
Murine peritoneal macrophages were treated with either 10(Z)-hexadecenoic acid (200 µM) or 668 
vehicle. Following a 12 h period after stimulation with lipopolysaccharide (LPS), total RNA 669 
content was measured using RNA-seq. (A) Heat map of the top 20 differentially expressed 670 
transcripts. (B) and (C) Genes significantly (B) upregulated or (C) downregulated with treatment 671 
of 10(Z)-hexadecenoic acid were separately queried on the Database for Annotation, 672 
Visualization and Integrated Discovery (DAVID). (B) The top five Kyoto Encyclopedia of 673 
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Genes and Genomes (KEGG) pathways enriched for genes upregulated following pretreatment 674 
of LPS-stimulated macrophages with 10(Z)-hexadecenoic acid, relative to media pretreated, 675 
LPS-stimulated macrophages. (C) The top five KEGG pathways enriched for genes 676 
downregulated following pretreatment of LPS-stimulated macrophages with 10(Z)-hexadecenoic 677 
acid, relative to media pretreated, LPS-stimulated macrophages. (D) Pathway analysis using the 678 
entire transcriptional data set was performed with Gene Set Enrichment Analysis (GSEA). 679 
Pathways enriched for genes upregulated following pretreatment of LPS-stimulated macrophages 680 
with 10(Z)-hexadecenoic acid, relative to media-pretreated, LPS-stimulated macrophages, were 681 
visualized in a network built by their gene set overlap. The size of the network node represents 682 
the number of genes shared between the particular gene set and the transcription data. The 683 
weight of network edges represents the degree of gene set overlap. In the largest cluster of 684 
pathways enriched in genes upregulated with 10(Z)-hexadecenoic acid, lipid metabolism and 685 
peroxisome proliferator-activated receptors (PPARs) were implicated as some of the more salient 686 
pathways. Abbreviations: Adamtsl4, thrombospondin repeat-containing protein 1; AMPK, 5' 687 
AMP-activated protein kinase; Ch25h, cholesterol 25-hydroxylase; Cish, cytokine inducible SH2 688 
containing protein; Ctla2b, cytotoxic T-lymphocyte-associated protein 2-beta; Cyp26b1, 689 
cytochrome P450 family 26 subfamily B member 1; Dusp1, dual specificity phosphatase 1; 690 
ECM, extracellular matrix; F3, coagulation factor III; Flrt3, fibronectin leucine rich 691 
transmembrane protein 3; Hdc, histidine decarboxylase; Hp, haptoglobin; Il1b, interleukin 1 692 
beta; Il6, interleukin 6; LKB1, liver kinase B1; Mir5105, microRNA 5105; MTOR, mechanistic 693 
target of rapamycin kinase; Plbd1, phospholipase B domain containing 1; Plin2, perilipin 2; 694 
PPAR, peroxisome proliferator activated receptor; PPARA, peroxisome proliferator activated 695 
receptor alpha; Ptgs2, prostaglandin-endoperoxide synthase 2; RORA, RAR related orphan 696 
33 
 
receptor A; TNF, tumor necrosis factor; Tns1, tensin 1; Tsc22d3, Tsc22 domain family member 697 
3; Vnn3, vanin 3. 698 
 699 
Fig. 4. 10(Z)-hexadecenoic acid suppresses expression of transcription factors downstream 700 
of TLR4.  701 
Murine peritoneal macrophages were treated with either 10(Z)-hexadecenoic acid (200 μM) or 702 
vehicle for 1 h, then challenged with lipopolysaccharide (LPS; 1 μg/ml). Following a 12 h period 703 
after stimulation with LPS, mRNA was measured using RNA-seq. (A) From Gene Set 704 
Enrichment Analysis (GSEA; c2.all.v6.2), pathways enriched with genes downregulated 705 
following pretreatment of LPS-stimulated macrophages with 10(Z)-hexadecenoic acid, relative to 706 
media-pretreated, LPS-stimulated macrophages, were visualized in a network built by their gene 707 
set overlap. The size of the network node indicates the number of genes shared between the 708 
particular gene set and the transcription data from our study. The weight of network edges 709 
indicates the degree of gene set overlap between nodes. The color of the node indicates whether 710 
the genes in the gene set are upregulated in NF-κB pathways (blue), upregulated in IRF pathways 711 
(purple), ambiguously upregulated (gray), or downregulated (red). (B) Among the leading edges 712 
of enriched pathway gene sets, the occurrence of high ranking genes in either the NF-κB-713 
regulated network (blue) or IRF-regulated network (purple) (corresponding to data illustrated in 714 
panel A) are reported. (C) Genes included in the IRF_Q6 gene set (left; i.e., genes having at least 715 
one occurrence of the transcription factor binding site V$IRF_Q6 (v7.4 TRANSFAC) in the 716 
regions spanning up to 4 kb around their transcription starting sites) and the significant 10(Z)-717 
hexadecenoic acid-dependent differentially expressed genes with q < 0.1 (right) were queried 718 
against the Interferome database (v2.0) to identify their association with known interferon 719 
responses. The majority of genes in both gene sets are attributed to both Type I and Type II 720 
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interferon responses. Abbreviations: CCL2, C-C motif chemokine ligand 2; CXCL1, C-X-C 721 
motif chemokine ligand 1; CXCL2, C-X-C motif chemokine ligand 2; IER3, immediate early 722 
response 3; IFN, interferon; IFNA, interferon alpha; IFNB1, interferon beta 1; IKK, inhibitor of 723 
nuclear factor kappa B kinase; INHBA, inhibin subunit beta A; IL1A, interleukin 1 alpha; IL1B, 724 
interleukin 1 beta; IL1R, interleukin 1 receptor; IL6, interleukin 6; JUNB, junB proto-oncogene, 725 
AP-1 transcription factor subunit; LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; 726 
NFKB1, nuclear factor kappa B subunit 1; PLAUR, plasminogen activator, urokinase receptor; 727 
PSMB8, proteasome subunit beta 8; PSMB9, proteasome subunit beta 9; PSMB10, proteasome 728 
subunit beta 10; PSME1, proteasome activator subunit 1; PTGS2, prostaglandin-endoperoxide 729 
synthase 2; STAT3, signal transducer and activator of transcription 3; TNF, tumor necrosis 730 
factor. 731 
 732 
Fig. 5 Analysis of the effects of M. vaccae-derived lipids on peroxisome proliferator-733 
activated receptor (PPAR) α, PPARγ, PPARδ, and retinoic acid receptor (RAR) α signaling 734 
in transfection assays using COS-1 cells. 735 
(A) Relative activity of PPARα following incubation with the 1,2,3-tri[Z-10-736 
hexadecenoyl]glycerol (PI-70; TAG), monoacylglycerol, 1-[Z-10-hexadecenoyl]glycerol (PI-69; 737 
MAG), or 10(Z)-hexadecenoic acid (PI-71; FFA) for 18 h, expressed as relative luciferase 738 
activity, normalized to β-galactosidase activity. (B) Relative activity of PPARγ. (C) Relative 739 
activity of PPARδ. (D) Relative activity of RARα. Abbreviations and concentrations: AM580 740 
(RARα-specific agonist, 100 nM), GW1516 (PPARδ agonist, 1 µM), RSG, rosiglitazone 741 
(PPARγ agonist, 2.5 µM), troglitazone (PPARγ agonist, 10 µM), WY-14643 (PPARα agonist, 2 742 
µM). Data are representative of 2-3 replicates per experiment. 743 
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Fig. 6 PPARα is required for suppression of LPS-induced inflammation in macrophages. 744 
A peroxisome proliferator-activated receptor (PPAR) α, -γ, or -δ antagonist (GW 6471, GW 745 
9662, GSK 0660 respectively) or vehicle was applied to murine peritoneal macrophages 746 
followed by treatment with either 10(Z)-hexadecenoic acid (200 µM), vehicle, or dexamethasone 747 
(Dex; 10 µM), then stimulated with lipopolysaccharide (LPS; 1 µg/ml). (A) After 12 h, 748 
interleukin (IL) 6 was measured in the cell supernatant and reported relative to vehicle controls. 749 
(B) The necessity of PPARα was shown in a PPARα knock out (KO) model. Murine peritoneal 750 
macrophages from PPARα
-/-
 or WT mice were incubated with either 10(Z)-hexadecenoic acid 751 
(50 μM or 200 μM) or vehicle, then stimulated with LPS (1 µg/ml). #p < 0.05, Fisher’s least 752 
significant difference (LSD), relative to cells only treated with 10(Z)-hexadecenoic acid. *p < 753 
0.05 relative to KO. 754 
SUPPORTING INFORMATION TITLES AND CAPTIONS 755 
Table S1. Dose- and time-dependent effects of 10(Z)-hexadecenoic acid on secretion of IL-6 756 
from freshly isolated murine peritoneal macrophages stimulated with lipopolysaccharide.   757 
Table S2. Descriptive statistics of cDNA libraries and RNA-sequencing. 758 
Table S3. List of 203 differentially expressed genes between treatment with 10(Z)-759 
hexadecenoic acid and vehicle in LPS-stimulated macrophages (FDR-adjusted p < 0.1) 760 
Table S4. KEGG pathways and GO biological processes with associated genes that are 761 
significantly downregulated in LPS-stimulated murine macrophages preincubated with 762 
10(Z)-hexadecenoic acid, relative to LPS-stimulated murine macrophages preincubated 763 
with media.  764 
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Table S5. Top scoring KEGG pathways enriched for differentially expressed genes (q < 765 
0.1). 766 
Table S6. Top scoring KEGG pathway enrichment scores of 10(Z)-hexadecenoic acid 767 
treatment 768 
Table S7. Transcription factor binding site enrichment scores of 10(Z)-hexadecenoic acid 769 
treatment 770 
Table S8. Transcription factor binding site enrichment scores of DMEM (i.e., LPS 771 
exposure, in the absence of 10(Z)-hexadecenoic acid treatment) 772 
Table S9. Selective peroxisome proliferator-activated receptor (PPAR) antagonists and 773 
agonists. 774 
Table S10. Lipopolysaccharide-induced proinflammatory cytokine and chemokine ligand 775 
mRNAs downregulated by preincubation of freshly isolated murine peritoneal 776 
macrophages with 10(Z)-hexadecenoic acid (selected from 203 differentially expressed 777 
mRNAs) 778 
Fig. S1. 10(Z)-hexadecenoic acid alone has no detectable effect on IL-6 release.  779 
After isolation of peritoneal macrophages and incubation with 10(Z)-hexadecenoic acid for 1 h, 780 
macrophages were challenged with either lipopolysaccharide (LPS) or Dulbecco’s Modified 781 
Eagle Medium (DMEM; as control). There was no detectable effect of 10(Z)-hexadecenoic acid 782 
on interleukin (IL) 6 secretion in the cultures that did not receive LPS. Abbreviations: IL-6, 783 
interleukin 6; LPS, lipopolysaccharide. Data are representative of 3 replicates per condition. 784 
Fig. S2. Effect of 10(Z)-hexadecencoic acid on macrophage cell viability.  785 
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Sulforhodamine B (SRB) was used to assess cytotoxic effects of various concentrations of 786 
synthetic 10(Z)-hexadecenoic acid (10 µM, 50 µM, 125 µM, 250 µM, 500 µM, 1000 µM) after 787 
0, 6, 12, 24, 48, and 72 h of incubation with freshly isolated murine peritoneal macrophages. 788 
Percent control growth is expressed as % viability and is a ratio of the amount of growth that 789 
occurred with treatment over the amount of growth that occurred in media. One hundred percent 790 
indicates no differences in cell growth between treatment and media, whereas values below 791 
100% indicate that growth was impaired with treatment. Data are expressed as mean  SEM of 792 
3-7 mice per condition. 793 
 794 
Fig. S3. BioAnalyzer electropherograms of cDNA libraries used for RNA-sequencing. Total 795 
RNA content of 1x10
5
 macrophages was prepared for each sample utilizing separate macrophage 796 
preparations from n = 3 mice treated with vehicle (Dulbecco’s Modified Eagle Medium 797 
(DMEM; upper row) then challenged with 1µg/mL lipopolysaccharide (LPS) or n = 3 mice 798 
treated with 200 µM 10(Z)-hexadecenoic acid for 1 h, then challenged with 1µg/mL LPS. 799 
Macrophages were harvested 12 h following LPS challenge. Peaks at 35 bp and 10,380 bp are 800 
gel migration markers. 801 
 802 
Fig. S4. Effect of PPAR agonists and antagonists on macrophage cell viability.  803 
Sulforhodamine B (SRB) was used to assess cytotoxic effects of PPAR agonists (PPARα, WY-804 
14643; PPARγ, rosiglitazone (RSG); PPARδ, GW0742) or PPAR agonists and antagonists 805 
(PPARα, GW6471; PPARγ, GW9662; PPARδ, GSK0660). The agonists and antagonists were 806 
incubated with freshly isolated murine peritoneal macrophages at 2x their respective EC50 or 807 
IC50 (see Table S9). Percent control growth is expressed as % viability and is a ratio of the 808 
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amount of growth that occurred with treatment over the amount of growth that occurred in 809 
media. One hundred percent indicates no differences in cell growth between treatment and 810 
media, whereas values below 100% indicate that growth was impaired with treatment. Data are 811 
expressed as mean ± SEM of 3-7 mice per condition. 812 
Figure S5. Suppression of IL-6 in LPS-stimulated macrophages is achieved through 813 
activation of PPARα and reversed by addition of a PPARα antagonist. 814 
Murine peritoneal macrophages were incubated with peroxisome proliferator-activated receptor 815 
(PPAR) α antagonist (GW 6471), PPARγ antagonist (GW 9662), PPARδ antagonist (GSK 816 
0660), or Dulbecco’s Modified Eagle Medium (DMEM)/F-12. After a 1-h incubation, the cells 817 
were treated with the complementary agonist (PPARα: WY-14643, PPARγ: rosiglitazone; Rosi., 818 
PPARδ: GW 0742). For each agonist, four concentrations were assayed, 1x, 2x, 5x, and 10x the 819 
half-maximal effective concentration (EC50). The immune response was measured as the 820 
concentration of interleukin (IL) 6 in the cell supernatant relative to vehicle controls. #p < 0.05 821 
main effect of agonist + antagonist condition relative to agonist alone condition in a multifactor 822 
ANOVA. *p < 0.05, Fisher’s least significant difference (LSD), pairwise comparison relative to 823 
antagonist-treated cells. 824 
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Supplemental Tables 1196 
 1197 
Table S1. Dose- and time-dependent effects of 10(Z)-hexadecenoic acid on secretion of IL-6 1198 
from freshly isolated murine peritoneal macrophages stimulated with lipopolysaccharide.   1199 
Concentration P-values
1 
6h 12h 24h 
LMER t-test LMER t-test LMER t-test 
0.4 0.45488 0.1957 0.97506 0.6117 0.172346 0.08114 
4 0.12283 0.2779 0.754265 0.4239 0.810008 0.07019 
20 0.16382 0.04546* 0.011331* 0.07472 0.096179 0.103 
100 0.0616 0.03446* 0.000424*** 0.02735* 0.00377** 0.03797* 
500 0.62085 0.1786 0.000159*** 0.0195* 0.003926** 0.032* 
1000 0.01311* 0.002494** 2.12E-05*** 0.01586* 0.000405*** 0.028502* 
Statistical tests consisted of pairwise comparisons of raw IL-6 values relative to paired media 1200 
control values at the same time point (n = 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001, 1201 
two-tailed LMER or Student’s t-test. 
1
Abbreviations: LMER, linear mixed effects in R. 1202 
 1203 







DMEM(1) 144.9 378 56.6 
DMEM(2) 121 411 60.8 
DMEM(3) 204.6 394 47.4 
10H(1) 246 388 51.4 
10H(2) 280.9 402 62.8 
10H(3) 249.6 404 63.6 
60 
 
Abbreviations: 10H, 10(Z)-hexadecenoic acid; DMEM, Dulbecco’s Modified Eagle Medium 1205 
(DMEM)/F-12 1206 
 1207 
Table S3. List of 203 differentially expressed genes between treatment with 10(Z)-1208 
hexadecenoic acid and vehicle in LPS-stimulated macrophages (FDR-adjusted p < 0.1). 1209 
Log2Fold 
Change 
padj gene Ensembl ID Log2Fold 
Change 
padj gene  
2.155269 2.26E-21 Hp ENSMUSG00000031722 4.175519 0.006465 Gm807 ENSMUSG00000097848 
-2.09473 4.37E-19 Il6 ENSMUSG00000025746 0.866752 0.006465 Cpt1a ENSMUSG00000024900 
2.132848 3.67E-17 Tsc22d3 ENSMUSG00000031431 1.201891 0.006658 Havcr2 ENSMUSG00000020399 
-1.81185 8.08E-16 Ptgs2 ENSMUSG00000032487 -0.84047 0.006831 Zyx ENSMUSG00000029860 
-2.30575 4.38E-15 Cish ENSMUSG00000032578 1.679239 0.006937 Wee1 ENSMUSG00000031016 
1.986963 1.67E-14 Dusp1 ENSMUSG00000024190 1.318917 0.007903 Adrb2 ENSMUSG00000045730 
2.012712 1.86E-12 Adamtsl4 ENSMUSG00000015850 -1.02689 0.008108 Timp1 ENSMUSG00000001131 
-1.6455 1.98E-12 Mir5105 ENSMUSG00000093077 1.166393 0.008496 Foxred2 ENSMUSG00000016552 
-2.04621 2.63E-12 Vnn3 ENSMUSG00000020010 1.245321 0.009034 Jdp2 ENSMUSG00000034271 
1.578041 2.63E-12 Plin2 ENSMUSG00000028494 -0.8805 0.009042 Pim1 ENSMUSG00000024014 
-1.93629 5.09E-12 F3 ENSMUSG00000028128 0.881662 0.009058 Sgms1 ENSMUSG00000040451 
-2.8558 5.31E-12 Hdc ENSMUSG00000027360 1.272806 0.00933 Rims3 ENSMUSG00000032890 
-1.5767 6.48E-12 Il1b ENSMUSG00000027398 0.915219 0.009572 Prkar2b ENSMUSG00000002997 
-2.15506 7.97E-12 Flrt3 ENSMUSG00000051379 -1.60497 0.009607 Rnf180 ENSMUSG00000021720 
3.024984 2.40E-11 Ctla2b ENSMUSG00000074874 -2.14325 0.009652 Syt7 ENSMUSG00000024743 
1.811323 4.79E-11 Tns1 ENSMUSG00000055322 -1.6082 0.009895 Hspa1a ENSMUSG00000091971 
1.82332 1.45E-10 Klhl6 ENSMUSG00000043008 -1.02922 0.010112 Tfec ENSMUSG00000029553 
-1.53809 2.78E-10 Plbd1 ENSMUSG00000030214 -1.32561 0.010112 Zfp558 ENSMUSG00000074500 
-4.06225 4.95E-10 Cyp26b1 ENSMUSG00000063415 -0.78966 0.010112 Il1rn ENSMUSG00000026981 
61 
 
-2.35715 5.70E-10 Ch25h ENSMUSG00000050370 0.801393 0.010902 Dock10 ENSMUSG00000038608 
-1.4212 3.35E-09 Ccl7 ENSMUSG00000035373 0.858932 0.010902 Tgfbi ENSMUSG00000035493 
-1.34039 4.91E-09 Ccl2 ENSMUSG00000035385 0.788151 0.010902 Pla2g7 ENSMUSG00000023913 
-3.35822 6.81E-09 Car4 ENSMUSG00000000805 1.794042 0.010902 Srgap3 ENSMUSG00000030257 
1.750436 1.16E-08 Susd2 ENSMUSG00000006342 0.983421 0.010993 Abcc3 ENSMUSG00000020865 
-3.51502 2.92E-08 Adm ENSMUSG00000030790 -1.03832 0.012028 Dennd3 ENSMUSG00000036661 
-1.41666 4.57E-08 Il12a ENSMUSG00000027776 0.78379 0.013193 Man2a1 ENSMUSG00000024085 
1.394626 5.98E-08 Ppp1r12b ENSMUSG00000073557 1.561095 0.013193 Frmd4b ENSMUSG00000030064 
1.317669 7.23E-08 Dennd4c ENSMUSG00000038024 1.181418 0.013404 Per2 ENSMUSG00000055866 
-1.56573 7.86E-08 Gm10499 ENSMUSG00000073403 1.920189 0.013773 Kcnk13 ENSMUSG00000045404 
-1.76168 1.01E-07 Hbegf ENSMUSG00000024486 -0.80185 0.014517 Plk2 ENSMUSG00000021701 
1.619779 2.04E-07 Ms4a8a ENSMUSG00000024730 1.39729 0.014584 Nrg4 ENSMUSG00000032311 
-1.29736 2.22E-07 Itgax ENSMUSG00000030789 1.946616 0.016015 Fabp4 ENSMUSG00000062515 
-1.48148 3.26E-07 Ccl22 ENSMUSG00000031779 0.814942 0.018239 Adam8 ENSMUSG00000025473 
1.312963 5.18E-07 Glul ENSMUSG00000026473 -0.99463 0.018957 Slamf1 ENSMUSG00000015316 
-1.29094 6.75E-07 Iigp1 ENSMUSG00000054072 0.896952 0.01948 Plpp1 ENSMUSG00000021759 
1.426376 7.14E-07 Lpxn ENSMUSG00000024696 0.778795 0.01948 Cd47 ENSMUSG00000055447 
-1.30554 8.49E-07 Slc1a2 ENSMUSG00000005089 3.257959 0.019865 Saxo1 ENSMUSG00000028492 
1.555412 8.59E-07 Fos ENSMUSG00000021250 -2.11589 0.023245 Csf2 ENSMUSG00000018916 
-1.73463 1.06E-06 Scimp ENSMUSG00000057135 -0.83357 0.024354 Gm14023 ENSMUSG00000085498 
1.307021 1.18E-06 Slc43a2 ENSMUSG00000038178 1.256371 0.026556 Cdo1 ENSMUSG00000033022 
2.671207 1.26E-06 Ly6c2 ENSMUSG00000022584 -0.81499 0.027117 Ier3 ENSMUSG00000003541 
1.168314 2.02E-06 Lcn2 ENSMUSG00000026822 0.806704 0.029122 Dock5 ENSMUSG00000044447 
1.578367 2.97E-06 Fkbp5 ENSMUSG00000024222 -0.71877 0.029122 Ccl3 ENSMUSG00000000982 
1.370214 4.86E-06 Sepp1 ENSMUSG00000064373 0.851011 0.03319 Rassf2 ENSMUSG00000027339 
1.299991 5.32E-06 Sort1 ENSMUSG00000068747 -1.53448 0.03319 Schip1 ENSMUSG00000027777 
-1.24524 1.79E-05 Upp1 ENSMUSG00000020407 0.943748 0.034299 Alox5ap ENSMUSG00000060063 
62 
 
-1.1367 2.36E-05 Ccl6 ENSMUSG00000018927 0.738488 0.039546 Sdc4 ENSMUSG00000017009 
-1.35404 2.68E-05 Cnn3 ENSMUSG00000053931 -1.05575 0.043357 Olfm1 ENSMUSG00000026833 
-2.22194 2.86E-05 Gm5483 ENSMUSG00000079597 0.734737 0.044388 Mt2 ENSMUSG00000031762 
1.131171 3.65E-05 Ecm1 ENSMUSG00000028108 -0.71991 0.044388 Inhba ENSMUSG00000041324 
1.297072 3.65E-05 Cacna1d ENSMUSG00000015968 0.833112 0.044388 Ift57 ENSMUSG00000032965 
-1.28314 3.90E-05 Olr1 ENSMUSG00000030162 1.775472 0.044388 Fabp7 ENSMUSG00000019874 
-1.54507 4.24E-05 Ahr ENSMUSG00000019256 -0.78572 0.044388 Trim30c ENSMUSG00000078616 
-1.96156 4.34E-05 Car2 ENSMUSG00000027562 -0.68344 0.044485 Rpph1 ENSMUSG00000092837 
-2.66361 5.55E-05 Hspa1b ENSMUSG00000090877 0.75981 0.047915 Ezr ENSMUSG00000052397 
-1.0926 6.25E-05 Plaur ENSMUSG00000046223 -0.87194 0.048952 Cd83 ENSMUSG00000015396 
-1.22776 7.12E-05 Procr ENSMUSG00000027611 0.802102 0.048952 Gpcpd1 ENSMUSG00000027346 
1.463418 8.54E-05 Nav2 ENSMUSG00000052512 -0.72003 0.050936 Nfkb2 ENSMUSG00000025225 
-1.03592 0.000104 Tnf ENSMUSG00000024401 -1.8997 0.050936 Lrrc32 ENSMUSG00000090958 
-1.12432 0.000105 Serpinb2 ENSMUSG00000062345 0.746734 0.051435 Itga4 ENSMUSG00000027009 
-1.08005 0.000134 Clec7a ENSMUSG00000079293 -0.92303 0.051789 Cd86 ENSMUSG00000022901 
-3.0819 0.000134 Ccl17 ENSMUSG00000031780 -0.73811 0.051789 Cmklr1 ENSMUSG00000042190 
2.207158 0.000208 Orm1 ENSMUSG00000039196 -1.11436 0.051885 Il12b ENSMUSG00000004296 
1.323308 0.000232 Cd300a ENSMUSG00000034652 -1.98017 0.053401 Gm13872 ENSMUSG00000087185 
0.972281 0.00028 Saa3 ENSMUSG00000040026 0.784546 0.056288 Gm12840 ENSMUSG00000086320 
-1.20636 0.000281 Egr2 ENSMUSG00000037868 -0.70065 0.05698 Oasl1 ENSMUSG00000041827 
-0.95987 0.000319 Il1a ENSMUSG00000027399 -0.70774 0.05698 Irf8 ENSMUSG00000041515 
-1.62852 0.00032 Tnc ENSMUSG00000028364 -1.19175 0.058415 Frmd6 ENSMUSG00000048285 
1.004165 0.000329 Xdh ENSMUSG00000024066 0.849896 0.058415 Per1 ENSMUSG00000020893 
-0.97547 0.000451 Cmpk2 ENSMUSG00000020638 0.735235 0.059193 Hal ENSMUSG00000020017 
1.213513 0.000585 Htra1 ENSMUSG00000006205 -0.72158 0.059548 Wars ENSMUSG00000021266 
-1.53878 0.000656 Irf4 ENSMUSG00000021356 1.006913 0.062477 Mmp19 ENSMUSG00000025355 
-1.42269 0.000656 AA467197 ENSMUSG00000033213 -0.57969 0.062658 Gm10800 ENSMUSG00000075014 
63 
 
-2.07631 0.000696 Kazn ENSMUSG00000040606 -0.67963 0.065954 Nos2 ENSMUSG00000020826 
0.956982 0.000867 Cd24a ENSMUSG00000047139 -0.83535 0.066479 Csrnp1 ENSMUSG00000032515 
-0.89122 0.000958 Rmrp ENSMUSG00000088088 0.712094 0.068155 Gm26809 ENSMUSG00000097815 
-0.9802 0.001016 Ccl4 ENSMUSG00000018930 -0.78044 0.068155 Insig1 ENSMUSG00000045294 
3.903311 0.001194 Dnah12 ENSMUSG00000021879 -0.61444 0.070733  ENSMUSG00000045999 
1.169473 0.001524 Rin3 ENSMUSG00000044456 1.704424 0.071129 Bpifc ENSMUSG00000050108 
1.169244 0.001741 F13a1 ENSMUSG00000039109 0.701972 0.071129 Pdxk ENSMUSG00000032788 
-0.949 0.002022 Chst11 ENSMUSG00000034612 0.994597 0.071577 Trim29 ENSMUSG00000032013 
-0.9961 0.002166 Casp7 ENSMUSG00000025076 -0.8871 0.076468 Mmp13 ENSMUSG00000050578 
3.931076 0.002435 Bach2os ENSMUSG00000086150 0.991755 0.078103 Wipi1 ENSMUSG00000041895 
0.885144 0.002435 Lox ENSMUSG00000024529 1.00311 0.079388 Serinc5 ENSMUSG00000021703 
-1.66375 0.002486 Rhoh ENSMUSG00000029204 -1.25174 0.079543 Il1f9 ENSMUSG00000044103 
-1.24964 0.002515  ENSMUSG00000092773 -0.67556 0.080434 Nfkb1 ENSMUSG00000028163 
-1.08726 0.002887 Socs1 ENSMUSG00000038037 0.942972 0.080838 Syt11 ENSMUSG00000068923 
1.302178 0.003251 Paqr7 ENSMUSG00000037348 1.324205 0.080838 Klra2 ENSMUSG00000030187 
-0.90079 0.003254 Mmp12 ENSMUSG00000049723 -0.71767 0.082101 Tmem2 ENSMUSG00000024754 
-1.06355 0.003509 Csf3 ENSMUSG00000038067 0.734669 0.082101 Ergic1 ENSMUSG00000001576 
-2.35111 0.003653 Il11 ENSMUSG00000004371 -0.80694 0.08253 Wfs1 ENSMUSG00000039474 
-0.84287 0.003941 Rsad2 ENSMUSG00000020641 -0.68387 0.082531 Isg15 ENSMUSG00000035692 
-1.12922 0.004208 Timp3 ENSMUSG00000020044 -0.67778 0.083148 Cxcl3 ENSMUSG00000029379 
-2.03218 0.004208 Dcstamp ENSMUSG00000022303 -0.90013 0.086117 Fst ENSMUSG00000021765 
1.386263 0.00424 Mgll ENSMUSG00000033174 1.157447 0.087469 Apoc2 ENSMUSG00000002992 
-0.89309 0.004485 Dab2 ENSMUSG00000022150 0.80021 0.090822 Cyth3 ENSMUSG00000018001 
1.14163 0.005073 Mafb ENSMUSG00000028874 1.07939 0.090822 Col18a1 ENSMUSG00000001435 
0.940402 0.005073 Fgr ENSMUSG00000074622 -1.25793 0.091248 Osmr ENSMUSG00000022146 
-0.81843 0.006355 Cxcl2 ENSMUSG00000058427 -1.42935 0.091568 Alpk2 ENSMUSG00000032845 
-1.24059 0.006465 Ptgs2os2 ENSMUSG00000097754 -0.72425 0.09327 Axl ENSMUSG00000002602 
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    0.815505 0.095702 Aldh9a1 ENSMUSG00000026687 
    0.925759 0.095702 Cav1 ENSMUSG00000007655 
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Table S4. KEGG pathways and GO biological processes with associated genes that are significantly 1223 
downregulated in LPS-stimulated murine macrophages preincubated with 10(Z)-hexadecenoic 1224 





Inflammatory response (GO:0006954) 
chemokine (C-C motif) 
ligand 4 (Ccl4) 
colony stimulating factor 2 
(granulocyte-
macrophage)(Csf2) 
AXL receptor tyrosine 
kinase (Axl) 
chemokine (C-X-C motif) 
ligand 3 (Cxcl3) 
interleukin 1 beta (Il1b) colony stimulating factor 3 
(granulocyte) (Csf3) 
C-type lectin domain 
family 7, member a 
(Clec7a) 
cytochrome P450, family 
26, subfamily b, 
polypeptide 1 (Cyp26b1) 
nuclear factor of kappa 
light polypeptide gene 
enhancer in B cells 1, p105 
(Nfkb1) 
cytokine inducible SH2-
containing protein (Cish) 
chemokine (C-C motif) 
ligand 17 (Ccl17) 
interleukin 1 alpha (Il1a) 
nuclear factor of kappa 
light polypeptide gene 
enhancer in B cells 2, 
p49/p100 (Nfkb2) 
interleukin 11 (Il11) chemokine (C-C motif) 
ligand 2 (Ccl2) 
interleukin 1 beta (Il1b) 
prostaglandin-
endoperoxide synthase 2 
(Ptgs2) 
interleukin 12a (Il12a) chemokine (C-C motif) 
ligand 22 (Ccl22) 
interleukin 1 family, 
member 9 (Il1f9) 
tumor necrosis factor (Tnf) interleukin 12b (Il12b) chemokine (C-C motif) 
ligand 3 (Ccl3) 
interleukin 6 (Il6) 
 interleukin 6 (Il6) chemokine (C-C motif) 
ligand 4 (Ccl4) 
nitric oxide synthase 2, 
inducible (Nos2) 
 oncostatin M receptor 
(Osmr) 
chemokine (C-C motif) 
ligand 6 (Ccl6) 
nuclear factor of kappa 
light polypeptide gene 
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enhancer in B cells 2, 
p49/p100 (Nfkb2) 
 proviral integration site 1 
(Pim1) 
chemokine (C-C motif) 
ligand 7 (Ccl7) 
oxidized low density 
lipoprotein (lectin-like) 
receptor 1 (Olr1) 
 suppressor of cytokine 
signaling 1(Socs1) 
chemokine (C-X-C motif) 
ligand 2(Cxcl2) 
prostaglandin-
endoperoxide synthase 2 
(Ptgs2) 







  1232 
Table S5. Top scoring KEGG pathways enriched for differentially expressed genes (q < 1233 
0.1). 1234 


































































































mmu05143:African trypanosomiasis 5 2.57732 10.40431 0.010775 1.49226
5 










mmu05332:Graft-versus-host disease 5 2.57732 7.002903 0.040085 6.32105
7 




mmu04621:NOD-like receptor signaling 
pathway 
5 2.57732 6.502695 0.047851 8.15499
9 












4.50496 0.062425 11.772 
mmu04622:RIG-I-like receptor signaling 
pathway 
5 2.57732 5.355161 0.079744 15.4004
9 
mmu00910:Nitrogen metabolism 3 1.54639
2 
12.85239 0.122031 23.7337 












5.11089 0.206209 41.0717 
































Table S6. Top scoring KEGG pathway enrichment scores of 10(Z)-hexadecenoic acid 1236 
treatment. 1237 






KEGG_PEROXISOME 70 0.455491 1.776987 0 0.206677 0.202 
KEGG_PPAR_SIGNALING_PATHWAY 50 0.405869 1.523902 0.022688 0.965135 0.877 
71 
 
KEGG_CITRATE_CYCLE_TCA_CYCLE 26 0.458822 1.441984 0.062157 1 0.976 
KEGG_FATTY_ACID_METABOLISM 35 0.410082 1.418581 0.066784 1 0.985 
KEGG_PROPANOATE_METABOLISM 29 0.381988 1.262367 0.171735 1 1 
 1238 
Table S7. Transcription factor binding site enrichment scores of 10(Z)-hexadecenoic acid 1239 
treatment. 1240 






MYB_Q3 193 0.354277 1.630786 0 0.4669 0.462 
CREBP1_01 138 0.353955 1.554846 0.001592 0.570198 0.79 
MYB_Q5_01 199 0.327401 1.527497 0.003185 0.502861 0.861 
TGATTTRY_GFI1_01 196 0.329035 1.51785 0 0.417293 0.885 
PPARA_01 31 0.448403 1.497608 0.024433 0.41565 0.938 
 1241 
Table S8. Transcription factor binding site enrichment scores of DMEM (i.e., LPS 1242 
exposure, in the absence of 10(Z)-hexadecenoic acid treatment). 1243 
NAME SIZE ES NES NOM p-val FDR q-val FWER p-
val 
YAATNANRNNNCAG_UNKNOWN 111 -0.38331 -1.73728 0 0.188651 0.134 
GGAMTNNNNNTCCY_UNKNOWN 45 -0.45405 -1.72149 0 0.105558 0.147 
NFKB_Q6_01 196 -0.34847 -1.68059 0 0.110536 0.223 
NFKB_Q6 214 -0.33542 -1.63828 0 0.137538 0.345 
GGCNKCCATNK_UNKNOWN 110 -0.35338 -1.56007 0.002342 0.235213 0.583 
IRF_Q6 200 -0.31662 -1.53823 0.007916 0.237864 0.654 
NFKB_C 216 -0.30917 -1.53386 0 0.214951 0.676 
NFKAPPAB65_01 194 -0.30235 -1.46879 0.002611 0.363113 0.888 
NFKAPPAB_01 210 -0.29933 -1.4586 0.002786 0.356037 0.915 










According to manufacturer information. 1249 
Table S10. Lipopolysaccharide-induced proinflammatory cytokine and chemokine ligand 1250 
mRNAs downregulated by preincubation of freshly isolated murine peritoneal 1251 
macrophages with 10(Z)-hexadecenoic acid (selected from 203 differentially expressed 1252 
mRNAs). 1253 
 1254 


















 Antagonist Agonist 
 Name  IC50 Name EC50 
PPARα GW 6471 (Cat. 
No. 4618)   
0.24 µM
1 












































































































































Table S11. Significant enrichment of “immune system process” (GO: 0006955) in 1260 
lipopolysaccharide-induced mRNAs downregulated by preincubation of freshly isolated 1261 
murine peritoneal macrophages with 10(Z)-hexadecenoic acid.   1262 
 1263 
Ensemble ID Mean 
#Reads 
LPS (n =3) 
Mean #Reads 
s148.2ffa 
+LPS (n = 3) 
Log2 Fold-change p value Adjusted p value Gene 
ENSMUSG00000019256 124.9318 42.81153 -1.54507 1.08E-07 4.24E-05 Ahr 
ENSMUSG00000029379 8341.778 5214.664 -0.67778 0.000768 0.083148 Cxcl3  
ENSMUSG00000029204 49.42187 15.5984 -1.66375 1.01E-05 0.002486 Rhoh  
ENSMUSG00000041827 1097.95 675.5632 -0.70065 0.000454 0.05698 Oasl1  
ENSMUSG00000041515 775.8443 475.0327 -0.70774 0.000456 0.05698 Irf8  
75 
 
ENSMUSG00000004296 77.84137 35.95454 -1.11436 0.000405 0.051885 Il12b  
ENSMUSG00000042190 789.4998 473.3228 -0.73811 0.000402 0.051789 Cmklr1  
ENSMUSG00000027398 15956.74 5349.469 -1.5767 4.03E-15 6.48E-12 Il1b  
ENSMUSG00000027399 16533.28 8499.829 -0.95987 1.02E-06 0.000319 Il1a  
ENSMUSG00000058427 4726.055 2679.948 -0.81843 3.01E-05 0.006355 Cxcl2  
ENSMUSG00000035692 773.1049 481.2528 -0.68387 0.000759 0.082531 Isg15  
ENSMUSG00000022901 143.9578 75.92354 -0.92303 0.0004 0.051789 Cd86  
ENSMUSG00000018916 26.48043 6.109115 -2.11589 0.000154 0.023245 Csf2  
ENSMUSG00000038067 215.195 102.9609 -1.06355 1.51E-05 0.003509 Csf3  
ENSMUSG00000044103 50.60669 21.25181 -1.25174 0.000705 0.079543 Il1f9  
ENSMUSG00000000982 6693.382 4066.999 -0.71877 0.000199 0.029122 Ccl3  
ENSMUSG00000015316 164.228 82.4202 -0.99463 0.000122 0.018957 Slamf1  
ENSMUSG00000002602 383.6876 232.2509 -0.72425 0.000893 0.09327 Axl  
ENSMUSG00000054072 609.7951 249.2138 -1.29094 1.13E-09 6.75E-07 Iigp1  
ENSMUSG00000022303 33.02525 8.074181 -2.03218 1.89E-05 0.004208 Dcstamp  
ENSMUSG00000027776 714.3374 267.5763 -1.41666 5.7E-11 4.57E-08 Il12a  
ENSMUSG00000018930 602.5693 305.4475 -0.9802 3.75E-06 0.001016 Ccl4  
ENSMUSG00000021356 87.38355 30.07534 -1.53878 2.27E-06 0.000656 Irf4  
ENSMUSG00000035373 1181.631 441.2235 -1.4212 3.37E-12 3.35E-09 Ccl7  
ENSMUSG00000020641 2750.461 1533.472 -0.84287 1.74E-05 0.003941 Rsad2  
ENSMUSG00000018927 809.8237 368.3064 -1.1367 5.31E-08 2.36E-05 Ccl6  
ENSMUSG00000035385 5656.07 2233.662 -1.34039 5.18E-12 4.91E-09 Ccl2  
ENSMUSG00000030789 1173.119 477.3067 -1.29736 3.41E-10 2.22E-07 Itgax  
ENSMUSG00000031780 24.3371 2.874252 -3.0819 3.97E-07 0.000134 Ccl17  
ENSMUSG00000030162 279.057 114.6645 -1.28314 9.71E-08 0.000039 Olr1  
ENSMUSG00000031779 326.9606 117.0914 -1.48148 5.15E-10 3.26E-07 Ccl22  
ENSMUSG00000025225 916.256 556.2449 -0.72003 0.000385 0.050936 Nfkb2  
ENSMUSG00000050370 100.3056 19.57727 -2.35715 5.46E-13 5.7E-10 Ch25h  
ENSMUSG00000026981 3855.465 2230.31 -0.78966 5.76E-05 0.010112 Il1rn  
ENSMUSG00000024401 2098.107 1023.257 -1.03592 2.95E-07 0.000104 Tnf  
76 
 
ENSMUSG00000025746 1302.137 304.8466 -2.09473 4.19E-23 4.37E-19 Il6  
 1264 
  1265 
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Supplemental Figures 1266 
 1267 
 1268 
Fig. S1. 10(Z)-hexadecenoic acid alone has no detectable effect IL-6 release.  1269 
After isolation of peritoneal macrophages and incubation with 10(Z)-hexadecenoic acid for 1 h, 1270 
macrophages were challenged with either lipopolysaccharide (LPS) or Dulbecco’s Modified 1271 
Eagle Medium (DMEM; as control). There was no detectable effect of 10(Z)-hexadecenoic acid 1272 
on interleukin (IL) 6 secretion in the cultures that did not receive LPS. Abbreviations: IL-6, 1273 











Fig. S2. Effect of 10(Z)-hexadecencoic acid on macrophage cell viability.  1283 
Sulforhodamine B (SRB) was used to assess cytotoxic effects of various concentrations of 1284 
synthetic 10(Z)-hexadecenoic acid (10 µM, 50 µM, 125 µM, 250 µM, 500 µM, 1000 µM) after 1285 
0, 6, 12, 24, 48, and 72 h of incubation with freshly isolated murine peritoneal macrophages. 1286 
Percent control growth is expressed as % viability and is a ratio of the amount of growth that 1287 
occurred with treatment over the amount of growth that occurred in media. One hundred percent 1288 
indicates no differences in cell growth between treatment and media, whereas values below 1289 
100% indicate that growth was impaired with treatment. Data are expressed as mean ± SEM of 1290 


















Fig. S3. BioAnalyzer electropherograms of cDNA libraries used for RNA-sequencing.  1305 
 1306 
Total RNA content of 1x10
5
 macrophages was prepared for each sample utilizing separate 1307 
macrophage preparations from n = 3 mice treated with vehicle (Dulbecco’s Modified Eagle 1308 
Medium (DMEM; upper row) then challenged with 1µg/mL lipopolysaccharide (LPS) or n = 3 1309 
mice treated with 200 µM 10(Z)-hexadecenoic acid for 1 h, then challenged with 1µg/mL LPS. 1310 
Macrophages were harvested 12 h following LPS challenge. Peaks at 35 bp and 10,380 bp are 1311 
gel migration markers. For concentrations of cDNA and average fragment length for each 1312 
sample, see Table S2. 1313 






Fig. S4. Effect of PPAR agonists and antagonists on macrophage cell viability.  1318 
Sulforhodamine B (SRB) was used to assess cytotoxic effects of PPAR agonists (PPARα, WY-1319 
14643; PPARγ, rosiglitazone (RSG); PPARδ, GW0742) or PPAR agonists and antagonists 1320 
(PPARα, GW6471; PPARγ, GW9662; PPARδ, GSK0660). The agonists and antagonists were 1321 
incubated with freshly isolated murine peritoneal macrophages at 2x their respective EC50 or 1322 
IC50 (see Table S9). Percent control growth is expressed as % viability and is a ratio of the 1323 
amount of growth that occurred with treatment over the amount of growth that occurred in 1324 
media. One hundred percent indicates no differences in cell growth between treatment and 1325 
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media, whereas values below 100% indicate that growth was impaired with treatment. Data are 1326 




Fig. S5. Suppression of IL-6 in LPS-stimulated macrophages is achieved through activation 1331 
of PPARα and reversed by addition of a PPARα antagonist. 1332 
Murine peritoneal macrophages were incubated with peroxisome proliferator-activated receptor 1333 
(PPAR) α antagonist (GW 6471), PPARγ antagonist (GW 9662), PPARδ antagonist (GSK 1334 
0660), or Dulbecco’s Modified Eagle Medium (DMEM)/F-12. After a 1-h incubation, the cells 1335 
were treated with the complementary agonist (PPARα: WY-14643, PPARγ: rosiglitazone; Rosi., 1336 
PPARδ: GW 0742). For each agonist, four concentrations were assayed, 1x, 2x, 5x, and 10x the 1337 
half-maximal effective concentration (EC50). The immune response was measured as the 1338 
83 
 
concentration of interleukin (IL) 6 in the cell supernatant relative to vehicle controls. #p < 0.05 1339 
main effect of agonist + antagonist condition relative to agonist alone condition in a multifactor 1340 
ANOVA. *p < 0.05, Fisher’s least significant difference (LSD), pairwise comparison relative to 1341 
antagonist-treated cells. 1342 
 1343 
 1344 
 1345 
 1346 
